| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
337.28(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.27 - $11 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
3,349 |
299,872 |
| Total Sell Value |
$0 |
$0 |
$16,042 |
$230,089 |
| Total People Sold |
0 |
0 |
3 |
4 |
| Total Sell Transactions |
0 |
0 |
10 |
88 |
| End Date |
2025-09-04 |
2025-06-03 |
2024-12-03 |
2023-12-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hagen Brett R |
Chief Accounting Officer |
• – – |
2025-03-26 |
4 |
S |
$8.97 |
$8,135 |
D/D |
(907) |
1,925 |
|
72% |
|
| Samsara Biocapital, L.p. |
10% Owner |
– – • |
2025-03-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
11,448,081 |
|
- |
|
| Akkaraju Srinivas |
|
– • • |
2025-03-18 |
4 |
A |
$0.00 |
$0 |
I/I |
11,444,503 |
11,444,503 |
|
- |
|
| Patel Samir Chandrakant |
|
– • – |
2025-03-18 |
4 |
A |
$0.00 |
$0 |
I/I |
100,800 |
100,800 |
|
- |
|
| Patel Samir Chandrakant |
|
– • – |
2025-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
252,000 |
252,000 |
|
- |
|
| Ferrara Napoleone |
|
– • – |
2025-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
504,000 |
504,000 |
|
- |
|
| Feinsod Matthew |
Chief Medical Officer |
• – – |
2025-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,030 |
4,030 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2025-02-21 |
4 |
S |
$10.08 |
$967 |
D/D |
(96) |
2,832 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2025-02-21 |
4 |
S |
$10.08 |
$3,053 |
D/D |
(303) |
49,129 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2025-02-21 |
4 |
S |
$10.08 |
$1,068 |
D/D |
(106) |
6,517 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2025-01-23 |
4 |
S |
$9.45 |
$494 |
D/D |
(52) |
6,623 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2025-01-23 |
4 |
S |
$9.45 |
$1,226 |
D/D |
(129) |
49,432 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2025-01-23 |
4 |
S |
$9.45 |
$342 |
D/D |
(36) |
2,928 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2025-01-10 |
4 |
S |
$0.44 |
$431 |
D/D |
(979) |
1,139,915 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2025-01-10 |
4 |
S |
$0.44 |
$146 |
D/D |
(332) |
68,174 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2025-01-10 |
4 |
S |
$0.44 |
$180 |
D/D |
(409) |
153,541 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2024-12-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
57,549 |
346,348 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2024-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
57,549 |
153,950 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2024-11-19 |
4 |
S |
$0.55 |
$1,748 |
D/D |
(3,186) |
1,140,894 |
|
- |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2024-11-19 |
4 |
S |
$0.55 |
$4,775 |
D/D |
(8,706) |
723,363 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2024-11-19 |
4 |
S |
$0.55 |
$237 |
D/D |
(432) |
211,499 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2024-11-19 |
4 |
S |
$0.55 |
$304 |
D/D |
(554) |
68,506 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2024-11-05 |
4 |
S |
$0.86 |
$1,965 |
D/D |
(2,272) |
211,931 |
|
- |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2024-11-05 |
4 |
S |
$0.86 |
$9,176 |
D/D |
(10,609) |
732,069 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2024-11-05 |
4 |
S |
$0.86 |
$4,442 |
D/D |
(5,136) |
1,144,080 |
|
- |
|
361 Records found
|
|
Page 1 of 15 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (0.37%) 
